Piramal Pharma Limited received an Establishment Inspection Report from the US FDA for its manufacturing facility at Sellersville in the United States and the inspection has been successfully closed. The company disclosed the development to BSE and NSE on 9 July 2026 under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements Regulations 2015 referencing BSE scrip code 543635 and NSE symbol PPLPHARMA.
The Sellersville facility was inspected by the US FDA following an earlier intimation dated 10 May 2026 regarding the ongoing inspection at the site and the closure concludes the regulatory review process without any adverse observation carried forward. The facility forms part of Piramal Pharma Limited's contract development and manufacturing organisation network serving the US pharmaceutical market.
The company operates under CIN L24297MH2020PLC338592 with its registered office at Ananta Building Piramal Corporate Park Kurla West Mumbai 400070 Maharashtra India. The disclosure was signed by Maneesh Sharma Company Secretary and Compliance Officer confirming the successful closure of the US FDA inspection for the company's records and shareholder information.
Piramal Pharma Limited's Sellersville facility serves the US pharmaceutical market through contract development and manufacturing operations. The successful closure of the US FDA inspection concludes the regulatory review process that commenced with the intimation dated 10 May 2026.
Disclaimer: This article is based on company filings submitted to the Bombay Stock Exchange (BSE) and National Stock Exchange of India (NSE) and is for informational purposes only. It does not constitute investment advice or a recommendation. Investors should conduct their own research and consult a qualified financial advisor before making investment decisions.